ArticleFrontiers in pharmacology2025
Effect of gentiopicroside on endogenous formaldehyde homocysteine-pathway related proteins in rats with non-alcoholic steatohepatitis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) characterised by high prevalence, increasing incidence among younger individuals and poor prognosis. NASH pathophysiology is not completely understood, and at present, there are no viable pharmacological treatments for this condition in clinical practice. Gentiopicroside (GPS). Can alleviate NASH by reducing inflammatory responses, inhibiting oxidative stress and influencing blood lipid levels. Objective: To examine the preventive and therapeutic effects of gentiopicroside (GPS) on proteins and metabolites related to the endogenous formaldehyde-homocysteine (FA-HCY) pathway as well as on oxidative stress in NASH rats. Methods: A high-fat, high-sugar diet was used to create a NASH rat model, and the rats' liver weight, body weight and liver index levels were measured. Oil red O and hematoxylin and eosin (HE) stainings were used to detect pathological alterations in the rat livers. Serum biochemical kits were used to identify biochemical markers in the rat serum. Markers linked to oxidative stress and metabolites associated with the endogenous FA-HCY pathway index were identified using Enzyme-linked immunosorbent assays (ELISA) kits. Gas chromatography was employed to measure the amount of endogenous FA in the liver and serum. Western blotting and real-time (RT) PCR were used to determine the relative expression levels of proteins and mRNAs associated with the endogenous FA-HCY pathway in rat liver tissues. Immunofluorescence was used to measure the relative fluorescence intensities of the proteins MTHFR, MAT1A and ALDH2. Results: A diet rich in fats and sugars results in weight gain and considerable steatosis. GPS can mitigate hepatic steatosis in NASH rats, reduce NAFLD activity scores and decrease the oil red O-stained area. The NASH rats' serum biochemical markers should be improved. In groups treated with GPS (low, medium and high dosages), the serum exhibited increased HDL-C levels ( Conclusion: The GPS has therapeutic benefits in NASH rats as it improves liver weight, body weight, liver index levels, liver steatosis and liver function. The efficacy of GPS in ameliorating NASH in rats may be associated with the modulation of the endogenous FA-HCY pathway and attenuation of oxidative stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.